Justin Kozak is the Executive VP at Founder Shield, a tech-enabled commercial insurance brokerage. He leads the Life Sciences practice, having 10+ years of experience in risk management with Hub International, PBC, and now Founder Shield. He launched his career with a BS in History from the University of Delaware, where his keen understanding of the past informs his intuition in the insurance world. It’s no surprise that Justin’s specialty is customizing insurance programs for emerging markets with little historical data. He enjoys spending time with his young family and can’t get enough of the Phillies.
With the global market for anti-obesity drugs projected to hit $95 billion by 2030, it’s no surprise that compounded semaglutide is gaining traction as a cheaper, more accessible option. But for all its appeal, this route comes with real risks: regulatory uncertainty, legal exposure, and major insurance hurdles.